These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34519817)

  • 1. Potential New Immune-Checkpoint Inhibitor Partner for Lung Cancer.
    Abbasi J
    JAMA; 2021 Sep; 326(10):901. PubMed ID: 34519817
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
    Gataa I; Mezquita L; Rossoni C; Auclin E; Kossai M; Aboubakar F; Le Moulec S; Massé J; Masson M; Radosevic-Robin N; Alemany P; Rouanne M; Bluthgen V; Hendriks L; Caramella C; Gazzah A; Planchard D; Pignon JP; Besse B; Adam J
    Eur J Cancer; 2021 Mar; 145():221-229. PubMed ID: 33516050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances and future perspectives in adjuvant and neoadjuvant immunotherapies for lung cancer.
    Yotsukura M; Nakagawa K; Suzuki K; Takamochi K; Ito H; Okami J; Aokage K; Shiono S; Yoshioka H; Aoki T; Tsutani Y; Okada M; Watanabe SI;
    Jpn J Clin Oncol; 2021 Jan; 51(1):28-36. PubMed ID: 33147608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC].
    El-Ghazzi N; Lavaud P
    Bull Cancer; 2021 Mar; 108(3):231-233. PubMed ID: 33622569
    [No Abstract]   [Full Text] [Related]  

  • 5. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for esophageal cancer: a 2019 update.
    Schizas D; Charalampakis N; Kole C; Mylonas KS; Katsaros I; Zhao M; Ajani JA; Psyrri A; Karamouzis MV; Liakakos T
    Immunotherapy; 2020 Feb; 12(3):203-218. PubMed ID: 32208794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of patients with melanoma using interleukin-2, interleukin-4 and tumor infiltrating lymphocytes.
    Hum Gene Ther; 1992 Apr; 3(2):167-77. PubMed ID: 1391037
    [No Abstract]   [Full Text] [Related]  

  • 8. Adoptive immunotherapy for nonsmall cell lung carcinoma. A fourth treatment modality, complicated radiation sensitizer, or none of the above.
    Karp DD; Atkins MB
    Cancer; 1996 Jul; 78(2):195-8. PubMed ID: 8673991
    [No Abstract]   [Full Text] [Related]  

  • 9. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
    Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
    Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment with autologous tumor-infiltrating lymphocytes and recombinant interleukin-2 in patients with lung carcinoma].
    Li D; Zhang X; Song Y
    Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):152-5. PubMed ID: 7656811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AA amyloidosis associated with pulmonary squamous cell carcinoma treated with chemoradiation and immune checkpoint inhibitor therapy.
    Mo H; Yau D; Mirshahidi H; Guadiz T; Zuppan CW; Magaki S
    Pathol Int; 2020 May; 70(5):303-305. PubMed ID: 32118332
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy with the use of tumor-infiltrating lymphocytes and interleukin-2 as adjuvant treatment in stage III non-small-cell lung cancer. A pilot study.
    Ratto GB; Melioli G; Zino P; Mereu C; Mirabelli S; Fantino G; Ponte M; Minuti P; Verna A; Noceti P
    J Thorac Cardiovasc Surg; 1995 Jun; 109(6):1212-7. PubMed ID: 7776685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage.
    Fukuda R; Sugawara S; Kondo Y
    Intern Med; 2020 Sep; 59(18):2245-2248. PubMed ID: 32522918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report.
    Fiorica F; Belluomini L; Giuliani J; Urbini B; Milella M; Frassoldati A; Pilotto S; Giorgi C
    Immunotherapy; 2021 Aug; 13(12):971-976. PubMed ID: 34180714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors.
    Furuta H; Kato S; Masago K; Hida T
    Clin Lung Cancer; 2021 Nov; 22(6):e829-e832. PubMed ID: 34023207
    [No Abstract]   [Full Text] [Related]  

  • 17. Real-world data on patients with metastatic non-small-cell lung cancer treated with checkpoint inhibitors in an Italian Teaching Hospital in 2015-2018.
    Veraldi M; Esposito S; Naturale MD; Oradei M; Cosco D; Francesco AE; Cicchetti A; Bidino RD
    J Oncol Pharm Pract; 2021 Jun; 27(4):877-886. PubMed ID: 32686615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
    Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
    Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD8-positive peripheral T cell lymphoma in a patient following long-term nivolumab for advanced lung adenocarcinoma: A case report.
    Koda K; Toyoshima M; Yazawa S; Fukada A; Sugimura H; Suda T
    Thorac Cancer; 2021 Jun; 12(11):1765-1769. PubMed ID: 33939308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
    Kagawa Y; Furuta H; Uemura T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Inaba Y; Kodaira T; Masago K; Fujita S; Niimi A; Hida T
    Cancer Sci; 2020 Dec; 111(12):4442-4452. PubMed ID: 32770608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.